GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (WBO:UCB) » Definitions » Cash Receipts from Fees and Commissions

UCB (WBO:UCB) Cash Receipts from Fees and Commissions


View and export this data going back to 2018. Start your Free Trial

What is UCB Cash Receipts from Fees and Commissions?

Cash Receipts from Fees and Commissions only applicable to companies reporting Cash Flow from Operations in direct method.


UCB (WBO:UCB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (WBO:UCB) » Definitions » Cash Receipts from Fees and Commissions
Address
Allee de la Recherche, 60, Brussels, BEL, B-1070
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).